Allogene Therapeutics, Inc. Stock price

Equities

ALLO

US0197701065

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-02-28 pm EST 5-day change 1st Jan Change
5.12 USD -0.39% Intraday chart for Allogene Therapeutics, Inc. +15.32% +59.50%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
limited-time offer
Enjoy this offer
* See conditions on site
Sales 2023 * 133K Sales 2024 * 74.82K Capitalization 862M
Net income 2023 * -312M Net income 2024 * -298M EV / Sales 2023 * 3,139 x
Net cash position 2023 * 443M Net cash position 2024 * 155M EV / Sales 2024 * 9,438 x
P/E ratio 2023 *
-2.55 x
P/E ratio 2024 *
-2.92 x
Employees 360
Yield 2023 *
-
Yield 2024 *
-
Free-Float 66.77%
More Fundamentals * Assessed data
Dynamic Chart
Allogene Therapeutics to Restate Financial Statements Due to Accounting Adjustments MT
Allogene Therapeutics, Inc. Announces Restate Financial Statements for the Years Ended December 31, 2020, 2021 and 2022 and Interim Quarters During 2022 and 2023 CI
HC Wainwright Adjusts Allogene Therapeutics Price Target to $10 From $12, Maintains Buy Rating MT
Transcript : Allogene Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
North American Morning Briefing : Boeing Drags -2- DJ
B. Riley Adjusts Allogene Therapeutics' PT to $10 From $15 on Heels of Announced Strategic Shift to Focus on New Study for Large B-cell Lymphoma, Keeps Buy Rating MT
Allogene Therapeutics to Lay off 22% of Workforce; Partners With Foresight to Develop in Vitro Diagnostic MT
Allogene Therapeutics Planning to Cut Roughly 22% of Workforce MT
JMP Securities Downgrades Allogene Therapeutics to Market Perform From Market Outperform MT
Allogene to cut 22% of its workforce RE
Transcript : Allogene Therapeutics, Inc. - Special Call
Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-Based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma CI
Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of Car T Led by ALPHA3 CI
Allogene Therapeutics, Inc.(NasdaqGS:ALLO) dropped from S&P Biotechnology Select Industry Index CI
Allogene Therapeutics, Inc. Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 CI
More news
1 day-0.39%
1 week+15.32%
Current month+45.45%
1 month+58.02%
3 months+98.45%
6 months+35.45%
Current year+59.50%
More quotes
1 week
4.32
Extreme 4.315
5.38
1 month
3.42
Extreme 3.42
5.38
Current year
2.61
Extreme 2.61
5.38
1 year
2.23
Extreme 2.23
6.89
3 years
2.23
Extreme 2.23
39.12
5 years
2.23
Extreme 2.23
55.00
10 years
2.23
Extreme 2.23
55.00
More quotes
Managers TitleAgeSince
Founder 64 18-03-31
Founder 47 17-10-31
Founder 52 -
Members of the board TitleAgeSince
Director/Board Member 81 18-04-30
Founder 47 17-10-31
Founder 74 17-10-31
More insiders
Date Price Change Volume
24-02-28 5.12 -0.39% 1,574,077
24-02-27 5.14 +11.02% 2,598,268
24-02-26 4.63 +1.98% 2,636,823
24-02-23 4.54 +4.13% 1,347,446
24-02-22 4.36 -1.80% 2,961,221

Delayed Quote Nasdaq, February 28, 2024 at 04:00 pm EST

More quotes
Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company. The Company is focused on the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer. It is engaged in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced T cell manufacturing technologies. Its advanced product candidates, ALLO-501 and ALLO-501A, are engineered allogeneic CAR T cell therapies that target CD19, a protein expressed on the cell surface of B cells and a validated target for B cell-driven hematological malignancies. It is also developing engineered allogeneic CAR T cell product candidates for multiple myeloma, clear cell renal cell carcinoma (ccRCC), and other blood cancers and solid tumors. Its lead product candidates include ALLO-501, ALLO-501A, ALLO-715, ALLO-605, ALLO-316, and ALLO-647.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
5.12 USD
Average target price
11.67 USD
Spread / Average Target
+127.86%
Consensus
  1. Stock
  2. Equities
  3. Stock Allogene Therapeutics, Inc. - Nasdaq
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW